Description
Carmetadin (Trimethazidine Dihydrochloride) Coated Tablets with Prolonged Release 35 mg. №60
Composition
The active ingredient in Carmetadin is trimethazidine dihydrochloride. Each tablet contains 35 mg of trimethazidine dihydrochloride.
Mechanism of Action
Trimethazidine dihydrochloride acts by improving cellular metabolism and shifting energy production from fatty acid oxidation to glucose oxidation, thereby reducing the oxygen consumption of the ischemic myocardium.
Pharmacological Properties
Carmetadin exerts anti-ischemic effects by preserving intracellular homeostasis and improving myocardial glucose utilization, leading to enhanced cardiac function and reduced ischemic damage.
Indications for Use
Carmetadin is indicated for the treatment of ischemic heart disease, specifically angina pectoris, to alleviate symptoms and improve exercise tolerance in patients with stable angina.
Contraindications
Carmetadin is contraindicated in patients with known hypersensitivity to trimethazidine or any other ingredient in the formulation. It is also contraindicated in patients with severe renal impairment due to the risk of drug accumulation and potential adverse effects on renal function.
Side Effects
The common side effects of Carmetadin may include gastrointestinal disturbances, such as nausea, vomiting, and abdominal discomfort. Rarely, allergic reactions or neurological symptoms like dizziness and headache may occur. If any adverse reactions persist or worsen, consult your healthcare provider.
Usage Instructions
Take one tablet of Carmetadin (35 mg) orally twice daily, preferably with meals. Swallow the tablets whole with a full glass of water. It is important to take this medication regularly as prescribed by your doctor to achieve optimal therapeutic benefits. If a dose is missed, take it as soon as you remember, but do not double the dose to make up for the missed one.
Benefits Compared to Analogues
Carmetadin offers the advantage of prolonged release formulation, providing sustained therapeutic levels of trimethazidine dihydrochloride in the body. This may result in improved patient compliance and better symptom control compared to immediate-release formulations.
Suitable Patient Groups
Carmetadin can be used in adult patients with stable angina pectoris who require anti-ischemic therapy. It is generally well-tolerated and can be prescribed to elderly patients and those with stable renal function. However, caution is advised in patients with severe hepatic impairment or certain metabolic disorders.
Storage and Shelf Life
Store Carmetadin in a cool, dry place away from direct sunlight and moisture. Keep the tablets in the original packaging to protect them from environmental factors. Check the expiration date on the packaging and do not use the tablets beyond the stated shelf life.
Packaging Description
Carmetadin is supplied in blister packs containing 60 coated tablets of 35 mg trimethazidine dihydrochloride each. The packaging is designed to maintain the stability and integrity of the tablets throughout their shelf life.
